Patent intelligence · US
US 11975029
Compositions and methods for inhibition of lineage specific proteins
Compositions and methods for inhibition of lineage specific proteins
Patent details — US 11975029
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 7, 2024
- Expiration
- May 2, 2044
- Applicant
- Vor Biopharma Inc.
- Claims
- 19
- CPC classes
- A61K, A61K2239/38, A61K2239/48, A61K35/17
Quick answer
US 11975029 (Compositions and methods for inhibition of lineage specific proteins) is held by Vor Biopharma Inc.. Status: granted. Granted May 7, 2024. Expires May 2, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vor Biopharma Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2239/38, A61K2239/48, A61K35/17, A61K35/28, A61K40/11
More from Vor Biopharma Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403200
Methods and compositions for treating autoimmune diseases
granted -
US 12291576
Anti-CD45 antibodies and conjugates thereof
granted -
US 12251403
Genetically engineered hematopoietic stem cells and uses thereof
granted -
US 12209135
Anti-CD45 antibodies and conjugates thereof
granted -
US 11903973
Genetically engineered hematopoietic stem cells and uses thereof
granted -
US 11571445
Genetically engineered hematopoietic stem cells and uses thereof
granted -
US 11559551
Genetically engineered hematopoietic stem cells and uses thereof
granted
Frequently asked questions
What is US patent 11975029?
US 11975029 (Compositions and methods for inhibition of lineage specific proteins) is held by Vor Biopharma Inc.. Status: granted. Granted May 7, 2024. Expires May 2, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11975029?
Vor Biopharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 11975029 expire?
Our index shows an expiration date of May 2, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.